Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest news about CSL Behring aggregated by PharmaCompass.com.

    Client Virtual Booth

    CSL BEHRING

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Formulations

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    CSL Behring
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    HQ; 1020 First AvenueA
    Telephone
    Telephone
    +1 610-878-4000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.cslbehring.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    left grey arrow
    right gray arrow
    Full View ScreenFull Screen View
    CSL Behring cuts headcount by 65 at Illinois plant
    CSL Behring cuts headcount by 65 at Illinois plant

    https://www.fiercepharma.com/manufacturing/csl-behring-shuts-down-filling-department-lays-65-staffers-major-illinois-site

    Zoey Becker FIERCE PHARMA
    15 Apr 2024
    Share Share
    Kyowa's Orchard hopes $4.25M gene therapy price tag bears fruit
    Kyowa's Orchard hopes $4.25M gene therapy price tag bears fruit

    https://www.fiercepharma.com/pharma/kyowa-kirins-orchard-sets-new-gene-therapy-price-tag-425m-steepest-any-drug-us

    Fraiser Kansteiner FIERCE PHARMA
    20 Mar 2024
    Share Share
    CSL and uniQure unveil three-year data for one-time hemophilia B gene therapy
    CSL and uniQure unveil three-year data for one-time hemophilia B gene therapy

    https://endpts.com/csl-and-uniqures-three-year-hemgenix-data-show-consistent-effect-in-hemophilia-b/

    ENDPTS
    09 Feb 2024
    Share Share
    CSL Behring Announces Availability of Hizentra 10g Prefilled Syringe
    CSL Behring Announces Availability of Hizentra 10g Prefilled Syringe

    https://www.prnewswire.com/news-releases/csl-behring-announces-availability-of-hizentra-immune-globulin-subcutaneous-human-20-liquid-10g-prefilled-syringe-302024891.html

    PR NEWSWIRE
    03 Jan 2024
    Share Share
    CSL Behring Demonstrates Continued Commitment to Alpha-1 Community
    CSL Behring Demonstrates Continued Commitment to Alpha-1 Community

    https://www.prnewswire.com/news-releases/csl-behring-demonstrates-continued-commitment-to-alpha-1-community-with-addition-of-zemaira-alpha1-proteinase-inhibitor-human-4--and-5-gram-vials-302024123.html

    PR NEWSWIRE
    02 Jan 2024
    Share Share
    FDA, EMA accept Pfizer's hemophilia B gene therapy
    FDA, EMA accept Pfizer's hemophilia B gene therapy

    https://endpts.com/fda-ema-accept-pfizers-hemophilia-b-gene-therapy-setting-up-showdown-with-csl-behring/

    Paul Schloesser ENDPTS
    27 Jun 2023
    Share Share
    CSL doses first patient with haemophilia B gene therapy Hemgenix
    CSL doses first patient with haemophilia B gene therapy Hemgenix

    https://www.pharmaceutical-technology.com/news/csl-first-patient-hemgenix-haemophilia-b/

    Aidan McNamee PHARMACEUTICAL TECHNOLOGY
    21 Jun 2023
    Share Share
    CSL's Hemgenix (Etranacogene Dezaparvovec) Receives Approval in Europe
    CSL's Hemgenix (Etranacogene Dezaparvovec) Receives Approval in Europe

    https://www.ema.europa.eu/en/documents/overview/hemgenix-epar-medicine-overview_en.pdf

    EMA
    20 Jun 2023
    Share Share
    CSL Behring Announces the First Patient Has Received FDA-Approved HEMGENIX
    CSL Behring Announces the First Patient Has Received FDA-Approved HEMGENIX

    https://www.prnewswire.com/news-releases/csl-behring-announces-the-first-patient-has-received-fda-approved-hemgenix-etranacogene-dezaparvovec-drlb-for-hemophilia-b-301854676.html

    PR NEWSWIRE
    20 Jun 2023
    Share Share
    CSL Behring Receives FDA Approval for Hizentra®
    CSL Behring Receives FDA Approval for Hizentra®

    https://www.prnewswire.com/news-releases/csl-behring-receives-fda-approval-for-hizentra-immune-globulin-subcutaneous-human-20-liquid-50ml-prefilled-syringe-301799492.html

    PR NEWSWIRE
    18 Apr 2023
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search